ArGEN-X: Forging The Future Of Antibodies
Logribel Biostocks - at Seeking Alpha - Tue Jun 09, 1:14PM CDT
SHPG: 250.34 (+7.35), ABBV: 69.23 (+1.26), NVS: 103.22 (+3.20), GLPG: 53.06 (+0.56)
Ablynx's (ABLYF) CEO Edwin Moses on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Feb 26, 2:19PM CST
Small companies lead the I-O class of Cancer Therapies
ACCESSWIRE - Fri Aug 08, 7:02AM CDT
Los Angeles, CA / August 8, 2014 / Tumor cells, tending to persist after treatment, lead to remission and have been a bane to cancer researchers and doctors for decades. Only recently, immuno-oncology, labeled 'I-O' first by Bristol-Myers Squibb Company (NYSE:BMY) has emerged to become a new class of cancer medicines that may someday take a meaningful place alongside chemotherapy, surgery, and radiation.
CLSN: 2.30 (+0.10), NWBO: 10.82 (+0.49), CVM: 0.67 (+0.04), CLDX: 24.89 (+0.42), INCY: 108.33 (+0.22), AZN: 66.45 (+1.90), MRK: 57.95 (+0.57), NLNK: 46.82 (+2.23), PPHM: 1.29 (+0.06), BMY: 69.27 (+1.38), FPRX: 26.01 (+0.37)